Medicus Pharma reports validation of SkinJect skin cancer trial data

March 30, 2026 7:30 AM

Medicus Pharma Ltd. (NASDAQ: MDCX) announced that Dr. Babar Rao, principal investigator of its Phase 2 SkinJect trial, validated the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found